Axcella Health, Inc.

Hepatic Encephalopathy: Emerging Therapies and Clinical Trials Highlighted

6 months ago

• Several companies are actively developing novel therapies for hepatic encephalopathy (HE), a neuropsychiatric condition resulting from advanced liver dysfunction. • Key players like Salix Pharmaceuticals and Vedanta Biosciences are advancing treatments such as Xifaxan and VE-303, showing promise in clinical trials. • Emerging therapies focus on innovative mechanisms like gut microbiota modulation and ammonia-lowering agents to improve patient outcomes. • Clinical trials are assessing various routes of administration and molecule types to address the unmet needs in HE treatment.